Table 1.
Correlation of CD147, VEGF, MMP-2 and MMP-9 expression with clinical features in GCT
| Clinical features | No. | CD147 | P | VEGF | P | MMP-2 | P | MMP-9 | P | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||||||||||
| - | + | ++ | +++ | + | ++ | +++ | + | ++ | +++ | + | ++ | +++ | ||||||
| Gender | ||||||||||||||||||
| Male | 32 | 3 | 8 | 16 | 5 | 0.886 | 8 | 19 | 5 | 1.000 | 12 | 14 | 6 | 1.000 | 6 | 12 | 14 | 0.700 |
| Female | 36 | 4 | 11 | 14 | 7 | 15 | 19 | 2 | 9 | 15 | 11 | 9 | 12 | 15 | ||||
| Age(years) | ||||||||||||||||||
| ≤20 | 11 | 0 | 4 | 5 | 2 | 0.115 | 3 | 6 | 2 | 0.285 | 3 | 5 | 3 | 0.156 | 4 | 3 | 4 | 0.126 |
| 21~ | 36 | 7 | 9 | 16 | 4 | 13 | 20 | 3 | 16 | 10 | 10 | 8 | 10 | 18 | ||||
| 41~ | 21 | 0 | 6 | 9 | 6 | 7 | 12 | 2 | 2 | 14 | 5 | 3 | 11 | 7 | ||||
| Jaffe stage | ||||||||||||||||||
| I | 24 | 4 | 7 | 8 | 5 | 0.045* | 13 | 9 | 2 | 0.21 | 8 | 10 | 5 | 0.032* | 5 | 9 | 10 | 0.050 |
| II | 37 | 3 | 10 | 18 | 6 | 7 | 27 | 3 | 12 | 16 | 10 | 8 | 13 | 16 | ||||
| III | 7 | 0 | 2 | 4 | 1 | 3 | 2 | 2 | 1 | 4 | 2 | 2 | 2 | 3 | ||||
| Prognosis | ||||||||||||||||||
| Normal | 50 | 5 | 15 | 22 | 8 | 0.008* | 15 | 30 | 5 | 0.052 | 16 | 24 | 11 | 0.024* | 13 | 16 | 21 | 0.034* |
| Canceration | 3 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 2 | ||||
| Recurrence | 14 | 2 | 3 | 6 | 3 | 6 | 7 | 1 | 3 | 6 | 5 | 1 | 7 | 6 | ||||
| Transfer | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | ||||
*
P<0.05.